Intramural Funding Opportunities
Deadline: April 23
Pfizer-CTI RFA (download application template)
Two funding types are available for collaboration: (1) Early proof-of-concept funding and (2) Multi-year joint programs (up to five years) to discover new therapeutics.
Deadline: May 7
Calico Cancer Research RFA
Calico’s oncology group is seeking opportunities for sponsored research or collaboration within the labs of outstanding academic investigators who are pursuing cancer-relevant science in areas of mutual interest.
Deadline: May 8
Breast Cancer Research RFA
Innovative proposals are invited that will make a major impact on breast cancer. Areas of interest include new treatment strategies and approaches to overcoming drug resistance but other innovative and high-risk approaches that may improve outcomes will also be considered.
Deadline: April 30
The Shurl & Kay Curci Foundation Faculty Scholars Program
This program is designed for early career faculty whose research and expertise align with the IGI’s scientific strategy of advancing biomedical applications with precision genomics.
LOI due: June 4
The Mark Foundation for Cancer Research - Emerging Leader Awards
These signature three-year academic grants totaling $750,000 will provide support to early career investigators conducting high-risk, high-impact cancer research. Eligible applicants must be within 3 - 8 years from the start of their independent research appointment.
Deadline: June 11
The Vilcek Foundation will award three prizes of $50,000 each to young foreign-born biomedical scientists who demonstrate outstanding early achievement. Eligible work may be in basic, applied, and/or translational biomedical science.
- Due June 5: Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional) (PA-18-729)
- Due June 16: Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional) (PA-18-728)
- Due June 19: Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) (PAR-18-731)
To view all NCI funding opportunities, search here